American College of Cardiology

NOVEMBER 7, 2024

The goal of the EMPEROR-Preserved trial was to assess the safety and efficacy of empagliflozin in patients with symptomatic heart failure with preserved ejection fraction (HFpEF), irrespective of diabetes status.

Preserved Ejection Fraction 57

Preserved Ejection Fraction Heart Failure Diabetes Outcomes 57

Cardiovascular Diabetology

MARCH 21, 2025

Heart failure (HF) with preserved ejection fraction (HFpEF) is increasingly prevalent worldwide due to aging and comorbidities. Epicardial adipose tissue (EAT), favored by diabetes and obesity, was shown to co.

Preserved Ejection Fraction 52

Preserved Ejection Fraction Heart Failure Obesity Diabetes 52

Cardiovascular Diabetology

AUGUST 30, 2024

Heart failure with preserved ejection fraction (HFpEF) is common in type 2 diabetes mellitus (T2D), leading to high morbidity and mortality. Managing HFpEF in diabetic patients is challenging with limited trea.

Preserved Ejection Fraction 59

Preserved Ejection Fraction Heart Failure Diabetes Research 59

Frontiers in Cardiovascular Medicine

NOVEMBER 17, 2024

BackgroundAnemia is a common complication in patients with heart failure and is associated with left ventricular systolic dysfunction.

Preserved Ejection Fraction 59

Preserved Ejection Fraction Heart Failure Tricuspid Atrial Fibrillation 59

DAIC

JUNE 21, 2024

announced that the peer-reviewed Journal of the American College of Cardiology: Heart Failure has published a research paper concluding that INPEFA (sotagliflozin) is cost-effective for people with diabetes and recent worsening heart failure using commonly accepted willingness-to-pay thresholds. “Our

Heart Failure 105

Heart Failure Preserved Ejection Fraction Diabetes Research 105

Cardiovascular Diabetology

NOVEMBER 4, 2024

Aging is influenced by genetic determinants and comorbidities, among which diabetes increases the risk for heart failure with preserved ejection fraction. There is no therapy to prevent heart dysfunction in ag.

Preserved Ejection Fraction 52

Preserved Ejection Fraction Cardiac Function Heart Dysfunction Heart Failure 52

DAIC

MARCH 25, 2025

Ten presentations will feature new data from the pivotal Phase III FINEARTS-HF cardiovascular (CV) outcomes trial, which investigated KERENDIA for treatingt adult patients with heart failure (HF) with a left ventricular ejection fraction (LVEF) of 40%, i.e., mildly reduced LVEF (HFmrEF) or preserved LVEF (HFpEF).

Preserved Ejection Fraction 52

Preserved Ejection Fraction Heart Failure Research Academic 52

Journal of the American Heart Association

FEBRUARY 19, 2025

BackgroundLimited studies show an association between elevated total homocysteine (tHcy) and heart failure (HF) risk, but no studies have assessed whether this association differs by HF subtype. Cox proportional hazards regression was used to calculate hazard ratios and 95% CI for tHcy and risk of HF.

Atherosclerosis 75

Atherosclerosis Heart Failure Preserved Ejection Fraction Diabetes 75

Circulation: Heart Failure

JANUARY 28, 2025

Circulation: Heart Failure, Ahead of Print. BACKGROUND:The therapeutic armamentarium for heart failure with preserved ejection fraction (HFpEF) remains notably constrained. compared with single condition exposure 5.21.3% (obesity), 6.73.5% (hypertension), and 9.01.1% (diabetes;P<0.001).

Preserved Ejection Fraction 40

Preserved Ejection Fraction Heart Failure Obesity Diabetes 40

American College of Cardiology

JANUARY 15, 2025

Alison Bailey and Milton Packer examine the power of tirzepatide expanding beyond weight loss and treating diabetes in addition to reducing heart failure events in patients with obesity-related HFpEF. In this interview, Drs.

Preserved Ejection Fraction 44

Preserved Ejection Fraction Heart Failure Obesity Diabetes 44

European Journal of Heart Failure

DECEMBER 7, 2023

Increasing severity of obesity is associated with multiple characteristics that may contribute to the development or worsening of heart failure (HF) with preserved ejection fraction (HFpEF). Obesity was associated with more first and recurrent heart failure events.

Preserved Ejection Fraction 40

Preserved Ejection Fraction Obesity Heart Failure BMI 40

Cardiovascular Diabetology

OCTOBER 18, 2024

Type 2 diabetes mellitus (T2DM) is a major risk factor for heart failure with preserved ejection fraction and cardiac arrhythmias. Precursors of these complications, such as diabetic cardiomyopathy, remain inc.

Preserved Ejection Fraction 52

Preserved Ejection Fraction Diabetes Heart Failure Risk Factors 52

American College of Cardiology

NOVEMBER 18, 2024

What is the incremental benefit in patients with heart failure and preserved ejection fraction (HFpEF) of glucagon-like peptide-1 receptor agonists (GLP-1 RA) combined with sodium-glucose cotransporter 2 inhibitors (SGLT2i) in patients with type 2 diabetes mellitus (T2DM) and body mass index (BMI) ≥27?

Preserved Ejection Fraction 67

Preserved Ejection Fraction BMI Heart Failure Diabetes 67

Circulation

OCTOBER 13, 2023

BACKGROUND:Apparent treatment-resistant hypertension (aTRH) is prevalent and associated with adverse outcomes in heart failure with mildly reduced or preserved ejection fraction. Less is known about the potential role of sodium-glucose co-transporter 2 inhibition in this high-risk population.

Preserved Ejection Fraction 40

Preserved Ejection Fraction Heart Failure Hypertension Myocardial Infarction 40

European Journal of Heart Failure

OCTOBER 9, 2023

Impact of COVID-19 in patients with HF and mildly reduced and preserved ejection fraction. COVID-19, coronvirus disease-2019; HF, heart failure. Aim COVID-19 may affect clinical risk in patients with heart failure. DELIVER began before and was conducted during the COVID-19 pandemic.

Preserved Ejection Fraction 40

Preserved Ejection Fraction COVID-19 Heart Failure Hospital 40

European Journal of Heart Failure

MARCH 4, 2024

Patients with heart failure and mildly reduced or preserved ejection fraction (HFmrEF/HFpEF) have a high risk of developing LRTI. Prior studies were able to show that sodium–glucose cotransporter 2 inhibitors may reduce the incidence of LRTI in patients with type 2 diabetes.

Preserved Ejection Fraction 40

Preserved Ejection Fraction Heart Failure COVID-19 Kidney Disease 40

American College of Cardiology

APRIL 10, 2024

What are the effects of semaglutide across a broad range of outcomes in people with obesity-related heart failure with preserved ejection fraction (HFpEF) with and without diabetes, and consistency across key patient subgroups?

Preserved Ejection Fraction 53

Preserved Ejection Fraction Obesity Heart Failure Diabetes 53

Circulation: Heart Failure

NOVEMBER 25, 2024

Circulation: Heart Failure, Volume 17, Issue 12 , Page e011629, December 1, 2024. Spironolactone, a steroidal mineralocorticoid receptor antagonist (MRA), has been used to treat patients with heart failure (HF) for more than half a century.

Preserved Ejection Fraction 40

Preserved Ejection Fraction Heart Failure Myocardial Infarction Kidney Disease 40

American College of Cardiology

JUNE 24, 2024

Semaglutide reduces body weight to a greater extent in women with obesity-related heart failure with preserved ejection fraction (HFpEF) than in men, and improved Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS) to the same extent in both women and men, according to results from a prespecified secondary analysis of pooled (..)

Preserved Ejection Fraction 59

Preserved Ejection Fraction Obesity Heart Failure Cardiomyopathy 59

Cardiovascular Diabetology

AUGUST 15, 2024

Patients with diabetes have an increased risk of developing heart failure with preserved ejection fraction (HFpEF). This study aimed to compare indices of myocardial deformation and perfusion between patients.

Preserved Ejection Fraction 52

Preserved Ejection Fraction Heart Failure Diabetes Research 52

Circulation

NOVEMBER 11, 2024

Background:Left ventricular global longitudinal strain (GLS) has been associated with mortality and heart failure hospitalization (HFH) among subjects with chronic heart failure, but not in patients with acute decompensated heart failure (ADHF). years, 50.6%

Preserved Ejection Fraction 40

Preserved Ejection Fraction Heart Failure Diabetes Pulmonary 40

Open Heart

NOVEMBER 27, 2023

Introduction This study aimed to evaluate the use and dose of loop diuretics (LDs) across the entire ejection fraction (EF) spectrum in a large, ‘real-world’ cohort of chronic heart failure (HF) patients. Among all LDs users, the median FDE was 40 mg (IQR: 40–80).

Heart Failure 52

Heart Failure Preserved Ejection Fraction Outpatient Diabetes 52

European Journal of Heart Failure

NOVEMBER 19, 2024

Hypertensive disorders of pregnancy as a risk factor for heart failure. Shortly after delivery, women who experienced HDP express increased risk of classic CV risk factors such as hypertension, renal disease, abnormal lipid profile, and diabetes.

Risk Factors 40

Risk Factors Heart Failure Hypertension Preserved Ejection Fraction 40

CardiacWire

AUGUST 2, 2024

Lilly’s blockbuster GLP-1 tirzepatide appears poised to become the next major HFpEF drug, after topline results from the SUMMIT trial showed that it significantly improved both outcomes and symptoms among patients with heart failure with preserved ejection fraction and obesity. vs. +15 KCCQ-CSS points).

Outcomes 59

Outcomes Preserved Ejection Fraction Heart Failure Obesity 59

European Journal of Heart Failure

MARCH 19, 2025

Semaglutide reduces late sodium current (I Na ) and diastolic calcium (Ca) sparks in human cardiomyocytes from aortic stenosis (AS) and end-stage heart failure with reduced ejection fraction (HFrEF) patients, thereby increasing Ca transients.

Preserved Ejection Fraction 40

Preserved Ejection Fraction Heart Failure Stenosis Aortic 40

DAIC

FEBRUARY 29, 2024

12:15 p.m.

Aortic valve 103

Aortic valve Myocardial Infarction Aortic Blood Pressure 103

Circulation: Cardiovascular Imaging

JANUARY 13, 2025

BACKGROUND:In patients with heart failure with preserved ejection fraction (HFpEF), the impact of type 2 diabetes (T2D) on left ventricular global longitudinal strain (LV GLS) and its prognostic implications remains unclear. Circulation: Cardiovascular Imaging, Ahead of Print.

Preserved Ejection Fraction 40

Preserved Ejection Fraction Cardiovascular Imaging Heart Failure Outcomes 40

Cardiometabolic Health Congress

JULY 25, 2023

There are significant data that show that if you have obesity, you have a high risk of developing coronary heart disease, heart failure, type 2 diabetes (T2D) or risk factors such as hypertension and dyslipidemia. [1] Is the obesity paradox a real phenomenon?

Obesity 52

Obesity BMI Heart Failure Cardiovascular Disease 52

Cardiology Update

APRIL 9, 2024

Investigators assessed if empagliflozin could lower the risk of hospitalization for heart failure (HF) or death from cardiovascular disease (CVD). STEP-HFpEF DM 5 ( NCT04916470 ) explored the effects of semaglutide in obesity-related HF with preserved ejection fraction (HFpEF) and type 2 diabetes.

Angina 52

Angina Myocardial Infarction Aortic valve Coronary Artery Disease 52

European Journal of Heart Failure

FEBRUARY 4, 2024

Abstract Aim Pathophysiological differences between patients with heart failure with preserved (HFpEF) and reduced (HFrEF) ejection fraction (EF) remain unclear. Study design and main study results. In HFrEF, interleukin (IL)-8 and IL-6 were possible targets related to lower EF and worsening renal function.

Preserved Ejection Fraction 40

Preserved Ejection Fraction Heart Failure Biomarkers Diabetes 40

Journal of the American Heart Association

JANUARY 23, 2025

Journal of the American Heart Association, Ahead of Print. BackgroundCardiometabolic comorbidities such as obesity, diabetes, and hypertension are highly prevalent in heart failure (HF). Severely uncontrolled comorbidities were defined as systolic blood pressure 160 mm Hg, hemoglobin A1c 8%, and body mass index 35 kg/m2.

Heart Failure 45

Heart Failure Preserved Ejection Fraction Obesity Outcomes 45

DAIC

JUNE 26, 2024

Getty Images milla1cf Wed, 06/26/2024 - 18:59 June 26, 2024 — Semaglutide , a medication initially developed for type 2 diabetes and obesity, significantly improves symptoms in men and women with a common type of heart failure that has had few therapeutic options.

Preserved Ejection Fraction 105

Preserved Ejection Fraction Obesity BMI Heart Failure 105

Cardiometabolic Health Congress

NOVEMBER 14, 2024

42% of adults are considered obese , increasing their risk of diabetes, hypertension, and cardiovascular issues. Additionally, 10% of the global population suffers from chronic kidney disease , with diabetes and hypertension as significant risk factors. In the U.S.,

CME 103

CME Obesity Heart Failure Biomarkers 103

Cardiometabolic Health Congress

NOVEMBER 22, 2024

Heart Failure Management : The FINEARTS-HF trial focused on the efficacy of finerenone, an aldosterone antagonist, in reducing heart failure hospitalizations and cardiovascular mortality among patients with preserved ejection fraction (HFpEF). Eckel, MD, FAHA, FACC at the 19th Annual CMHC.

Blood Pressure 59

Blood Pressure Obesity Preserved Ejection Fraction Coronary Artery Disease 59

The British Journal of Cardiology

JANUARY 14, 2025

We report from the 19 th Annual Scientific Meeting of the Cardiorenal Forum held in London on 4 th October 2024, which served as a dynamic platform for experts in cardiology, diabetes, and renal medicine to converge and exchange the latest insights on managing heart and kidney failure.

Innovation 40

Innovation Diabetes Preserved Ejection Fraction Outcomes 40